What challenges do Bavarian biotechnology and pharmaceutical companies have to master in the pandemic and are there opportunities arising from the increased attention from politics and society? What effects are they feeling and what measures have they taken? What support does the industry need and how many companies are actually dealing with the various pandemic issues?
As the management organization for the Bavarian biotechnology and pharmaceutical industry, BioM wants to provide the best possible support in overcoming the current challenges posed by the coronavirus pandemic.
For example, BioM was instrumental in initiating the Bavarian funding program to combat the COVID-19 pandemic, "BayTherapie2020."
As in the spring of 2020, we also conducted a company survey on the coronavirus pandemic this year. This snapshot of the situation within the Bavarian life science community allowed us to better assess the situation and capture developments since the 2020 survey.
For example, companies' concerns have fortunately eased noticeably, but supply bottlenecks have become a clear problem.
In 2020, 94 participants at executive level took part in the survey; in 2021, we received 62 responses.
The full analyses can be found at:
The insights gained from this survey help the BioM cluster management to tailor offers to demand; they have also been shared with political stakeholders at federal and state level as an important basis for decision-making.
The BioM team continues to address individual questions directly concerning how to cope with the special challenges posed by the pandemic.